Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;37(2):800-818.
doi: 10.1007/s12325-019-01186-z. Epub 2019 Dec 23.

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Petri Mankinen  1 , Tuomas Lundström  2 , Erkki Soini  2 , Marja-Liisa Sumelahti  3 , Juhani Ruutiainen  4   5 , Ulla Niskala  6 , Elina Järvinen  6   7
Affiliations

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis

Petri Mankinen et al. Adv Ther. 2020 Feb.

Abstract

Introduction: Cost assessment modelling (CAM) of treatments in highly active relapsing multiple sclerosis was conducted.

Methods: The CAM was developed using the R programming language. The PICOSTEPS health technology assessment framework was applied in the CAM. Modelled patients were 280 adults with highly active relapsing multiple sclerosis eligible for disease-modifying treatment. Intervention was cladribine tablets, a new and reimbursed oral treatment for highly active relapsing multiple sclerosis in Finland. Comparators included fingolimod, the most used oral reimbursed treatment for the highly active disease, and natalizumab, the most used intravenous treatment, and a treatment mix (80% use fingolimod, 20% use natalizumab) in Finland. Outcomes presented expected annual and cumulative drug-associated costs in the overall population and per patient. Setting was modelled public specialist care in Finland. Time was set to 4 years, without discounting. Effects covered expected drug-associated costs (screening, acquisition, administration, monitoring, adverse events, travelling, productivity). Perspective was a limited societal perspective. Sensitivity analyses regarding all PICOSTEPS components were conducted.

Results: Cladribine tablets were projected to be cost saving in comparison to fingolimod, natalizumab and treatment mix. The respective modelled savings were €4,598,742, €16,249,701 and €6,928,934 in the overall population, and €16,424, €58,035 and €24,746 per patient, respectively, during the 4 years. The most important cost driver was drug costs, representing 96.3%, 96.0% and 83.4% of modelled costs associated with cladribine tablets, fingolimod and natalizumab, respectively. Cladribine tablets sustained their affordability in the sensitivity analyses. From the perspective of health care payer, cladribine tablets' savings were projected to be €4,514,509, €15,145,366 and €6,640,680 in the overall population, and €16,123, €54,091 and €23,717 per patient in comparison to fingolimod, natalizumab and treatment mix, respectively.

Conclusion: Based on the CAM, cladribine tablets were projected to robustly save modelled drug-associated costs in comparison to fingolimod, natalizumab and their mix in Finland.

Keywords: Cladribine tablets; Cost; Fingolimod; Multiple sclerosis; Natalizumab; Productivity; Travelling.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Annual acquisition costs per patient
Fig. 2
Fig. 2
Drug-associated screening costs, and annual monitoring, administration, AEs, travelling, and productivity costs per patient. S = Screening
See this image and copyright information in PMC

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517. doi: 10.1016/S0140-6736(08)61620-7. - DOI - PubMed
    1. Lublin FD, Reingold SC, Cohen A, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560. - DOI - PMC - PubMed
    1. Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(11):1192–1198. doi: 10.1136/jnnp-2013-304951. - DOI - PubMed
    1. Diaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: an update. Mult Scler Relat Disord. 2019;30:215–224. doi: 10.1016/j.msard.2019.01.039. - DOI - PubMed
    1. Kaye HS, Kang T, LaPlante MP Mobility device use in the United States: disability statistics report 14. June 2000. https://files.eric.ed.gov/fulltext/ ED444296.pdf. Accessed 12 Feb 12, 2018.

Publication types

MeSH terms